Familial adenomatous polyposis (FAP) is an inherited susceptibility to diffuse colorectal adenomas and to colorectal carcinoma, occurring in close to 100% of unresected colons and is caused by a germline mutation in the APC gene. Most subjects who develop FAP show evidence of early adenomas between ages 10 and 15. The mutated APC gene also predisposes to duodenal polyps and to periampullary carcinoma. Although the standard of care has long been considered to be colectomy at diagnosis, practitioners and patients have been increasingly willing to undergo surveillance until there is evidence of progressive polyp burden. A recent trial demonstrated the activity of celecoxib in regressing prevalent adenomas in FAP patients with advanced adenomatous disease. This study will examine the natural history of the colorectal mucosa in young, asymptomatic carriers of APC mutations, and explore the role of celecoxib in suppressing emergence of the adenomatous phenotype. In addition, a number of ancillary evaluations will examine the relative impact of this potential preventive approach on the psychosocial status of patients.

Agency
National Institute of Health (NIH)
Institute
Division of Cancer Prevention And Control (NCI)
Type
Research and Development Contracts (N01)
Project #
N01CN005126-000
Application #
6357838
Study Section
Project Start
2000-09-30
Project End
2005-09-29
Budget Start
2000-09-30
Budget End
2001-09-29
Support Year
Fiscal Year
2000
Total Cost
$3,251,125
Indirect Cost
Name
University of Texas MD Anderson Cancer Center
Department
Internal Medicine/Medicine
Type
Other Domestic Higher Education
DUNS #
001910777
City
Houston
State
TX
Country
United States
Zip Code
77030
Lynch, Patrick M; Ayers, Gregory D; Hawk, Ernie et al. (2010) The safety and efficacy of celecoxib in children with familial adenomatous polyposis. Am J Gastroenterol 105:1437-43